vs
美敦力（MDT）与PILGRIMS PRIDE CORP（PPC）财务数据对比。点击上方公司名可切换其他公司
美敦力的季度营收约是PILGRIMS PRIDE CORP的2.0倍（$9.0B vs $4.5B），美敦力净利率更高（12.8% vs 2.2%，领先10.5%），美敦力同比增速更快（8.7% vs 1.6%），过去两年美敦力的营收复合增速更高（2.5% vs -0.3%）
美敦力是全球知名的医疗设备企业，法定及行政总部位于爱尔兰，运营总部设在美国明尼苏达州明尼阿波利斯。2015年集团收购爱尔兰企业柯惠后将注册地迁至爱尔兰，目前业务覆盖超150个国家，员工逾9万名，专注于研发生产各类医疗技术产品及治疗解决方案。
Pilgrim's Pride是美国跨国食品企业，为美国及波多黎各最大的鸡肉生产商之一，同时是墨西哥第二大鸡肉生产商。公司2009年12月脱离破产状态，2011年将美国总部迁至科罗拉多州格里利，由JBS集团控股，2016年11月底以3.5亿美元收购Gold'n Plump。
MDT vs PPC — 直观对比
营收规模更大
MDT
是对方的2.0倍
$4.5B
营收增速更快
MDT
高出7.2%
1.6%
净利率更高
MDT
高出10.5%
2.2%
两年增速更快
MDT
近两年复合增速
-0.3%
损益表 — Q4 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $9.0B | $4.5B |
| 净利润 | $1.1B | $101.5M |
| 毛利率 | — | 7.6% |
| 营业利润率 | 16.2% | 3.6% |
| 净利率 | 12.8% | 2.2% |
| 营收同比 | 8.7% | 1.6% |
| 净利润同比 | -11.7% | — |
| 每股收益（稀释后） | $0.89 | $0.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MDTPPC
| Q1 26 | $9.0B | $4.5B | ||
| Q4 25 | $9.0B | $4.5B | ||
| Q3 25 | $8.6B | $4.8B | ||
| Q2 25 | $8.9B | $4.8B | ||
| Q1 25 | $8.3B | $4.5B | ||
| Q4 24 | $8.4B | $4.4B | ||
| Q3 24 | $7.9B | $4.6B | ||
| Q2 24 | $8.6B | $4.6B |
净利润MDTPPC
| Q1 26 | $1.1B | $101.5M | ||
| Q4 25 | $1.4B | $88.0M | ||
| Q3 25 | $1.0B | $342.8M | ||
| Q2 25 | $1.1B | $355.5M | ||
| Q1 25 | $1.3B | $296.0M | ||
| Q4 24 | $1.3B | $235.9M | ||
| Q3 24 | $1.0B | $349.9M | ||
| Q2 24 | $654.0M | $326.3M |
毛利率MDTPPC
| Q1 26 | — | 7.6% | ||
| Q4 25 | 65.8% | 9.5% | ||
| Q3 25 | 65.0% | 13.9% | ||
| Q2 25 | 64.8% | 15.0% | ||
| Q1 25 | 66.5% | 12.4% | ||
| Q4 24 | 64.9% | 12.7% | ||
| Q3 24 | 65.1% | 14.9% | ||
| Q2 24 | 64.5% | 15.2% |
营业利润率MDTPPC
| Q1 26 | 16.2% | 3.6% | ||
| Q4 25 | 18.8% | 4.5% | ||
| Q3 25 | 16.8% | 10.4% | ||
| Q2 25 | 16.1% | 10.8% | ||
| Q1 25 | 19.9% | 9.1% | ||
| Q4 24 | 19.0% | 7.0% | ||
| Q3 24 | 16.1% | 11.1% | ||
| Q2 24 | 12.3% | 9.7% |
净利率MDTPPC
| Q1 26 | 12.8% | 2.2% | ||
| Q4 25 | 15.3% | 1.9% | ||
| Q3 25 | 12.1% | 7.2% | ||
| Q2 25 | 11.8% | 7.5% | ||
| Q1 25 | 15.6% | 6.6% | ||
| Q4 24 | 15.1% | 5.4% | ||
| Q3 24 | 13.2% | 7.6% | ||
| Q2 24 | 7.6% | 7.2% |
每股收益（稀释后）MDTPPC
| Q1 26 | $0.89 | $0.43 | ||
| Q4 25 | $1.07 | $0.37 | ||
| Q3 25 | $0.81 | $1.44 | ||
| Q2 25 | $0.81 | $1.49 | ||
| Q1 25 | $1.01 | $1.24 | ||
| Q4 24 | $0.99 | $1.00 | ||
| Q3 24 | $0.80 | $1.47 | ||
| Q2 24 | $0.50 | $1.37 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $542.4M |
| 总债务越低越好 | — | $3.1B |
| 股东权益账面价值 | — | $3.7B |
| 总资产 | — | $10.2B |
| 负债/权益比越低杠杆越低 | — | 0.83× |
8季度趋势，按日历期对齐
现金及短期投资MDTPPC
| Q1 26 | — | $542.4M | ||
| Q4 25 | $8.3B | $640.2M | ||
| Q3 25 | $8.1B | $612.6M | ||
| Q2 25 | $9.0B | $849.0M | ||
| Q1 25 | $7.9B | $2.1B | ||
| Q4 24 | $8.0B | $2.0B | ||
| Q3 24 | $7.8B | $1.9B | ||
| Q2 24 | $8.0B | $1.3B |
总债务MDTPPC
| Q1 26 | — | $3.1B | ||
| Q4 25 | $27.7B | $3.1B | ||
| Q3 25 | $26.2B | $3.1B | ||
| Q2 25 | $25.6B | $3.1B | ||
| Q1 25 | $24.0B | $3.2B | ||
| Q4 24 | $24.6B | $3.2B | ||
| Q3 24 | $26.3B | $3.2B | ||
| Q2 24 | $23.9B | $3.2B |
股东权益MDTPPC
| Q1 26 | — | $3.7B | ||
| Q4 25 | $48.7B | $3.7B | ||
| Q3 25 | $47.9B | $3.5B | ||
| Q2 25 | $48.0B | $3.7B | ||
| Q1 25 | $49.4B | $3.1B | ||
| Q4 24 | $48.5B | $4.2B | ||
| Q3 24 | $47.9B | $4.2B | ||
| Q2 24 | $50.2B | $3.7B |
总资产MDTPPC
| Q1 26 | — | $10.2B | ||
| Q4 25 | $91.3B | $10.3B | ||
| Q3 25 | $91.0B | $10.0B | ||
| Q2 25 | $91.7B | $10.1B | ||
| Q1 25 | $90.0B | $11.0B | ||
| Q4 24 | $90.0B | $10.7B | ||
| Q3 24 | $89.7B | $10.7B | ||
| Q2 24 | $90.0B | $10.1B |
负债/权益比MDTPPC
| Q1 26 | — | 0.83× | ||
| Q4 25 | 0.57× | 0.84× | ||
| Q3 25 | 0.55× | 0.87× | ||
| Q2 25 | 0.53× | 0.83× | ||
| Q1 25 | 0.49× | 1.02× | ||
| Q4 24 | 0.51× | 0.76× | ||
| Q3 24 | 0.55× | 0.76× | ||
| Q2 24 | 0.48× | 0.85× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.8B | — |
| 自由现金流经营现金流 - 资本支出 | $3.3B | — |
| 自由现金流率自由现金流/营收 | 37.1% | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 4.14× | — |
| 过去12个月自由现金流最近4个季度 | $6.5B | — |
8季度趋势，按日历期对齐
经营现金流MDTPPC
| Q1 26 | $4.8B | — | ||
| Q4 25 | $925.0M | $291.2M | ||
| Q3 25 | $1.1B | $458.3M | ||
| Q2 25 | $2.5B | $495.2M | ||
| Q1 25 | $2.6B | $126.9M | ||
| Q4 24 | $958.0M | $349.3M | ||
| Q3 24 | $986.0M | $651.1M | ||
| Q2 24 | $2.8B | $718.6M |
自由现金流MDTPPC
| Q1 26 | $3.3B | — | ||
| Q4 25 | $457.0M | $10.0M | ||
| Q3 25 | $584.0M | $275.9M | ||
| Q2 25 | $2.1B | $339.1M | ||
| Q1 25 | $2.1B | $28.1M | ||
| Q4 24 | $554.0M | $176.6M | ||
| Q3 24 | $466.0M | $565.3M | ||
| Q2 24 | $2.4B | $617.7M |
自由现金流率MDTPPC
| Q1 26 | 37.1% | — | ||
| Q4 25 | 5.1% | 0.2% | ||
| Q3 25 | 6.8% | 5.8% | ||
| Q2 25 | 23.2% | 7.1% | ||
| Q1 25 | 25.3% | 0.6% | ||
| Q4 24 | 6.6% | 4.0% | ||
| Q3 24 | 5.9% | 12.3% | ||
| Q2 24 | 27.4% | 13.5% |
资本支出强度MDTPPC
| Q1 26 | — | — | ||
| Q4 25 | 5.2% | 6.2% | ||
| Q3 25 | 5.9% | 3.8% | ||
| Q2 25 | 5.1% | 3.3% | ||
| Q1 25 | 5.7% | 2.2% | ||
| Q4 24 | 4.8% | 4.0% | ||
| Q3 24 | 6.6% | 1.9% | ||
| Q2 24 | 5.0% | 2.2% |
现金转化率MDTPPC
| Q1 26 | 4.14× | — | ||
| Q4 25 | 0.67× | 3.31× | ||
| Q3 25 | 1.05× | 1.34× | ||
| Q2 25 | 2.39× | 1.39× | ||
| Q1 25 | 1.99× | 0.43× | ||
| Q4 24 | 0.75× | 1.48× | ||
| Q3 24 | 0.95× | 1.86× | ||
| Q2 24 | 4.25× | 2.20× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MDT
| Cardiovascular Portfolio | $3.5B | 38% |
| Neuroscience Portfolio | $2.6B | 28% |
| Medical Surgical Portfolio | $2.2B | 24% |
| Diabetes business | $796.0M | 9% |
PPC
| U.S | $2.6B | 58% |
| Europe | $1.4B | 30% |
| Mexico | $545.5M | 12% |
